Trial reportArthritis research & therapy2019
Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
Trial report in Arthritis research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06622603 (A Prospective, Multicenter, Randomized Investigator Initiative Clinical Trial Study on the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Multicenter, Randomized Investigator Initiative Clinical Trial Study on the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia.Arthritis care & research · 2024Trial
- Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.Arthritis & rheumatology (Hoboken, N.J.) · 2022Trial
- The efficacy and safety of benzbromarone and febuxostat in combined-type hyperuricemia: a single-center study.Clinical rheumatology · 2026Article
- Targeting ALOX5 ameliorates renal tubular injury in ischemia-reperfusion-induced acute kidney injury via inhibition of ferroptosis.Communications biology · 2025Article
- Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score-Matched Cohort Study.Arthritis care & research · 2025Article
- Review
- [Diagnostics and treatment of gout : Short version of the German S3 guideline].Zeitschrift fur Rheumatologie · 2025Review
- Clinical observations on arthroscopic removal of urate deposits in the knee: a seven-case series.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025Article
- Analysis of the efficacy of multidisciplinary integration based on 3D reconstruction technology for the treatment of gout stone.Journal of orthopaedic surgery and research · 2025Article
- Efficacy of different dosages of common uric acid-lowering medications in gout patients: a network meta-analysis of randomized control trials.Frontiers in pharmacology · 2025Review
- The efficacy of a low-dose combination of febuxostat and benzbromarone versus each drug used alone for the treatment of gout.Frontiers in medicine · 2025Article
- Predictors of Inadequate Serum Urate Response to Low-Dose Febuxostat in Male Patients with Gout.Journal of inflammation research · 2024Article
- Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry.Scientific reports · 2023Article
- Febuxostat Therapy for Patients with Gout and Stage 2-4 CKD: a Retrospective Study.Rheumatology and therapy · 2022Article
- Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.Clinical rheumatology · 2022Article
- A historical journey of searching for uricosuric drugs.Clinical rheumatology · 2022Review
- Effects of fenofibrate therapy on renal function in primary gout patients.Rheumatology (Oxford, England) · 2021Article
- Observational
- Effect of Clinical Typing on Serum Urate Targets of Benzbromarone in Chinese Gout Patients: A Prospective Cohort Study.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLow doses of febuxostat or benzbromarone are widely used in Asian countries, but lacking studies to compare the efficacy and safety of the two urate-lowering drugs.
methodsTo compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China. Randomization was carried out by a third-party institution according to random number table. Patients were randomly assigned 1:1 to febuxostat group (Feb group) (20 mg daily) or benzbromarone group (Ben group) (25 mg daily) and treated for 12 weeks. General information and biochemical data were collected at baseline and at every visit monthly. Clinical characteristics before and after the ULT were analyzed in the two groups by SPSS and EmpowerStats software.
resultsTwo hundred forty patients were enrolled and randomized in the two groups, with 214 patients completing 12 weeks' ULT (105 in the Feb group and 109 in the Ben group). After 12 weeks, substantial percentages of patients in both Feb and Ben group achieved the target serum uric acid (sUA) (< 360 μmol/L) and serum urate levels were reduced significantly for both groups (Feb 39.5% and 156.83 μmol/L vs. Ben 35.7% and 163.99 μmol/L). Multivariate analysis suggests baseline sUA level and renal function were associated with the outcome of the rate of achieving target sUA (RAT). Sub-group analysis suggests low doses of febuxostat and benzbromarone rendered better RAT for patients with sUA < 540 μmol/L and creatinine clearance rate (Ccr) ≤ 110 mL min
conclusionOverall, febuxostat 20 mg daily and benzbromarone 25 mg daily reduced sUA, and gout patients with sUA level < 540 μmol/L or Ccr ≤ 110 mL min
trial registrationRegistered with ChiCTR, No. ChiCTR1800019352 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.